Financial Performance - Dongbao Biological reported a net profit decline of 28% year-on-year for the first half of 2025, with total revenue of 369 million yuan, down 16.93% compared to the previous year [1] - The gross profit margin increased to 25.44%, a year-on-year increase of 12.25%, while the net profit margin decreased to 10.02%, down 19.73% [1] - Total expenses (selling, administrative, and financial) reached 34.68 million yuan, accounting for 9.4% of revenue, which is a 56.8% increase year-on-year [1] Key Financial Metrics - Revenue for the second quarter of 2025 was 181 million yuan, a decrease of 10.61% year-on-year, with a net profit of 17.92 million yuan, down 29.38% [1] - The company’s cash and cash equivalents decreased by 34.72% to 521 million yuan, while accounts receivable increased by 16.46% to 191 million yuan [1] - The return on invested capital (ROIC) for the previous year was 3.79%, indicating weak capital returns, with a historical median ROIC of 3.16% over the past decade [3] Debt and Cash Flow - The company has a healthy cash position, but the interest-bearing debt ratio has reached 20.13% [4] - The accounts receivable to profit ratio is at 221.88%, indicating potential concerns regarding cash flow management [4] Operational Strategies - The company has implemented measures to enhance cost control, including optimizing supply chain management and improving supplier relationships [5] - Emphasis on quality control through a management philosophy focused on prevention, control, and improvement, aiming to ensure product quality and cost efficiency [5]

Core Insights - Dongbao Biological achieved operating revenue of 369 million yuan and a net profit attributable to shareholders of 36.97 million yuan in the first half of 2025 [1] - The company focuses on the natural collagen sector and implements a health development strategy amid uncertainties in the external environment, particularly in the gelatin market [1][2] - Dongbao Biological is actively responding to market challenges through product segmentation, exploring new application fields, and enhancing digital transformation [1][2] Financial Performance - In the first half of 2025, Dongbao Biological's revenue was 369 million yuan, with a net profit of 36.97 million yuan [1] - The company faced short-term declines in sales and prices due to fluctuations in the gelatin market [1] Strategic Initiatives - Dongbao Biological is enhancing its research and development system, focusing on demand-driven innovation and application breakthroughs [2] - The company is advancing various projects, including specialized collagen for cashmere textiles and low-endotoxin gelatin, which are in the process of market engagement [2] - The company is also pushing for the industrialization of hair care collagen products and expanding its product matrix into multiple application fields [2][3] Market Positioning - Dongbao Biological is committed to developing high-value-added collagen derivatives, maintaining its leading position in the natural collagen industry [3] - The company aims to evolve into a comprehensive enterprise group in the health industry, focusing on medical, beauty, health, and food sectors [3]

Core Viewpoint - Dongbao Biological reported a revenue of 369 million yuan and a net profit of 36.97 million yuan for the first half of 2025, demonstrating resilience in a complex market environment through strategic market exploration and cost reduction initiatives [1] Group 1: Market Strategy and Performance - The company focused on the collagen industry strategy, enhancing operational efficiency through refined management and organizational improvements [2] - Dongbao Biological initiated a stock repurchase plan, buying back 10.57 million shares, representing 1.78% of its total share capital, to enhance shareholder value and investor confidence [2] - The company achieved significant growth in its gelatin segment, particularly in the blood plasma gelatin market, and saw an increase in revenue from its hollow capsule products [2] Group 2: Product Development and Innovation - Key R&D projects made substantial progress, including improvements in anti-pilling levels for collagen used in cashmere textiles and advancements in low-endotoxin gelatin [3] - The company is advancing its collagen products for hair care and has initiated market connections for various modified gelatin applications [3] Group 3: Industry Outlook and Growth Potential - Despite short-term performance pressures, the company is well-positioned for long-term growth due to its comprehensive production capabilities, management advantages, and strong R&D platform [4] - The pharmaceutical excipients market, particularly for hollow capsules, is expected to expand due to policy support and technological innovations, benefiting leading companies like Dongbao Biological [4] - The growing health consciousness among consumers is driving demand for nutritional health products and beauty care, creating new opportunities for collagen applications [4] Group 4: Expanding Applications and Market Opportunities - The introduction of blood plasma gelatin is extending the company's applications into the medical field, with potential uses in various medical products and procedures [5] - The "Healthy China" initiative is fostering a supportive policy environment for the health industry, which is expected to enhance market demand for high-quality health products [5][6] - Dongbao Biological is positioned to benefit from the ongoing high-quality development in the health sector, leveraging its management, technology, and brand advantages [6]

Group 1 - Dongbao Biological (SZ 300239) announced on August 29 that its 12th meeting of the 9th board of directors was held on August 28, 2025, in Baotou, where the proposal to revise the "Information Disclosure Management System" was reviewed [1] - For the year 2024, Dongbao Biological's revenue composition is 100.0% from biological and biochemical products [1]

Core Viewpoint - Dongbao Bio (300239.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders of the listed company was 36.97 million yuan, reflecting a year-on-year decrease of 28.00% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 33.44 million yuan, down 27.41% year-on-year [1] - Basic earnings per share were reported at 0.0629 yuan [1]

Core Viewpoint - Dongbao Biological (300239.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 369 million yuan, a year-on-year decrease of 16.93% [1] - The net profit attributable to shareholders was 36.97 million yuan, down 28.00% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 33.44 million yuan, reflecting a 27.41% decline compared to the previous year [1] - Basic earnings per share were reported at 0.0629 yuan [1]

包头东宝生物技术股份有限公司关于募集资金 2025 年半年度存放与使用情况的专项报告 2025 年 1 月 1 日至 2025 年 6 月 30 日 （本专项报告除特别注明外，均以人民币元列示） 证券代码：300239 证券简称：东宝生物 公告编号：2025-060 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于募集资金2025年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 募集资金基本情况 （一） 向特定对象发行股票募集资金情况 1、 募集资金金额及到位时间 2021 年 5 月，经中国证券监督管理委员会证监许可[2020]3058 号文同意注册，并 经深圳证券交易所同意，本公司由主承销商招商证券股份有限公司采取向特定对象发行 的方式发行人民币普通股（A 股）7,272.89 万股，每股发行价格人民币 5.60 元，募集 资金总额为 407,281,700.00 元，扣除与发行有关的费用合计人民币 10,588,219.76 元 （不含税）后，募集资金净额为人民币 396,693,480. ...

2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算的 会计科目 | 2025年期初占 用资金余额 | 2025年半年度占 用累计发生金额 | 2025年半年度 占用资金的利 | 2025年半年度 偿还累计发生 | 2025年半年度 期末占用资金 | 占用形成原因 | 是否披露 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | （不含利息） | 息(如有） | 金额 | 余额 | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | | - | | 其他关联方及附属企业 | | | | | | | | ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司 2025 年半年度报告全文及摘要已于 2025 年 8 月 29 日在中国证监会指定的创业板信息披露网站(巨潮资讯网，网址： www.cninfo.com.cn)上披露，请投资者注意查看。 特此公告。 包头东宝生物技术股份有限公司 包头东宝生物技术股份有限公司 关于 2025 年半年度报告披露提示性公告 董事会 2025 年 8 月 29 日 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 第九届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、包头东宝生物技术股份有限公司(以下简称"公司")第九届董事会第十 二次会议通知于 2025 年 8 月 18 日以直接送达或电子邮件等方式通知了全体董事、 高级管理人员。 6、本次会议的召集、召开和表决程序符合法律、行政法规、部门规章、规 范性文件和公司《董事会议事规则》、《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 与会董事认真审阅了有关议案并进行了表决。经与会董事一致同意，形成决 议如下： 1、审议通过了《2025 年半年度报告全文及摘要》 经审议，董事会认为：公司 2025 年半年度报告全文及摘要真实、准确、完 整地反映了公司 2025 年半年度的实际经营情况，不存在任何虚假记载、误导性 陈述或重大遗漏，报告编制和审核程 ...